BLAINTRAVENOUSINJECTABLE1 Generic Approved
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
ENTYVIO (vedolizumab) by Takeda is integrin receptor antagonists [moa]. Approved for integrin receptor antagonist [epc]. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENTYVIO (vedolizumab) is a monoclonal antibody integrin receptor antagonist administered intravenously for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. It selectively blocks α4β7 integrin to reduce gut-homing lymphocytes and intestinal inflammation. The drug targets patients with moderate-to-severe disease who are inadequate responders to conventional or biologic therapies.
Growth
Product is in growth phase with moderate competitive intensity (30/100), indicating expanding commercial teams and field force investment opportunities.
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Started Oct 2025
70 enrolled
Ulcerative ColitisCrohn's Disease
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
Started Oct 2025
120 enrolled
Inflammatory Bowel Disease (IBD)Crohn&Amp;#39;s Disease (CD)Ulcerative Colitis (UC)
CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Retrospective Cohort Study
Started Sep 2025
400 enrolled
Ulcerative Colitis (UC)
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Started Jul 2025
80 enrolled
Immune Checkpoint Inhibitor-Related Colitis
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Started Jun 2025
573 enrolled
Ulcerative Colitis
Worked on ENTYVIO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.